Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The focus of most current HIV-1 vaccine development is on antibody-based approaches. This is because certain antibody responses correlated with protection from HIV-1 acquisition in the RV144 phase III trial, and because a series of potent and broad spectrum neutralizing antibodies have been isolated from infected individuals. Taken together, these two findings suggest ways forward to develop a neutralizing antibody-based vaccine. However, understanding of the correlates of protection from disease in HIV-1 and other infections strongly suggests that we should not ignore CTL-based research. Here we review recent progress in the field and highlight the challenges implicit in HIV-1 vaccine design and some potential solutions.

Original publication

DOI

10.1186/1742-4690-10-72

Type

Journal article

Journal

Retrovirology

Publication Date

17/07/2013

Volume

10

Keywords

AIDS Vaccines, Acquired Immunodeficiency Syndrome, Antibodies, Neutralizing, Clinical Trials as Topic, Drug Discovery, HIV Antibodies, HIV-1, Humans, T-Lymphocytes, Cytotoxic